(Total Views: 3065)
Posted On: 05/23/2024 11:15:20 AM
Post# of 148870
Dr Jay and Quest Clinical Research
Elsewhere others have noted and I can confirm Dr J put an end date of May 2024 to his LinkedIn profile for Quest Clinical Research. I use LinkedIn and the end dates don’t show up accidentally, they are established intentionally. That is his baby and there is nothing official, but if Dr J is handing over the reigns to the research organization he founded and under which he has performed countless clinical trials it would be for a good reason.
Dr J I believe is not singularly focused on money. I mentioned the below quote recently regarding Merck and you’ll recall PD-1 inhibitors don’t treat 85% of CCR to say nothing of other clinically devastating high CCR5 expressing tumors such as pancreatic and glioblastoma.
“ With Merck reporting a whopping $25 billion sales haul for Keytruda on Thursday, the PD-1 cancer superstar appears to be the world's top-selling drug in 2023.”
I am ill- equipped to get into Dr. Jay’s psyche and try to divine intentions but previous actions strongly suggest he is a healer first and wants Leronlimab in the hands of clinicians as a first order priority. Perhaps there is a juggernaut BP that has come knocking and dictating reasonable terms that go beyond money…”but we will need you fully committed”. It is why companies buy “key man” insurance. Yes, let’s make this happen, we will give you the keys to our treasury and vast resources but you must be Master and Commander to guide the trial…full time.
Dr. Jay has to have a good reason to step back from his baby if that is what is happening. This scenario would be a good reason. This would be a legacy, not in money although that is assumed, but in bringing Elysium to an honest man who wants to make a real difference to humanity and the many infirmities for which Leronlimab can make a difference.
Elsewhere others have noted and I can confirm Dr J put an end date of May 2024 to his LinkedIn profile for Quest Clinical Research. I use LinkedIn and the end dates don’t show up accidentally, they are established intentionally. That is his baby and there is nothing official, but if Dr J is handing over the reigns to the research organization he founded and under which he has performed countless clinical trials it would be for a good reason.
Dr J I believe is not singularly focused on money. I mentioned the below quote recently regarding Merck and you’ll recall PD-1 inhibitors don’t treat 85% of CCR to say nothing of other clinically devastating high CCR5 expressing tumors such as pancreatic and glioblastoma.
“ With Merck reporting a whopping $25 billion sales haul for Keytruda on Thursday, the PD-1 cancer superstar appears to be the world's top-selling drug in 2023.”
I am ill- equipped to get into Dr. Jay’s psyche and try to divine intentions but previous actions strongly suggest he is a healer first and wants Leronlimab in the hands of clinicians as a first order priority. Perhaps there is a juggernaut BP that has come knocking and dictating reasonable terms that go beyond money…”but we will need you fully committed”. It is why companies buy “key man” insurance. Yes, let’s make this happen, we will give you the keys to our treasury and vast resources but you must be Master and Commander to guide the trial…full time.
Dr. Jay has to have a good reason to step back from his baby if that is what is happening. This scenario would be a good reason. This would be a legacy, not in money although that is assumed, but in bringing Elysium to an honest man who wants to make a real difference to humanity and the many infirmities for which Leronlimab can make a difference.
(36)
(0)Scroll down for more posts ▼
